Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

07:13
11/23/16
11/23
07:13
11/23/16
07:13

Eli Lilly CEO says company disappointed, remains committed to Alzheimer's

Eli Lilly CEO John Lechleiter and incoming CEO David Ricks are being interviewed on CNBC after announcing earlier that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.

TODAY'S FREE FLY STORIES

NLNK

NewLink Genetics

$18.59

0.51 (2.82%)

, MRK

Merck

$62.55

0.405 (0.65%)

14:32
04/25/17
04/25
14:32
04/25/17
14:32
Hot Stocks
NewLink drops after panel questions Ebola vaccine efficacy »

Shares of NewLink…

NLNK

NewLink Genetics

$18.59

0.51 (2.82%)

MRK

Merck

$62.55

0.405 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 10

    May

  • 12

    May

  • 27

    May

  • 31

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

X

U.S. Steel

$31.19

-0.01 (-0.03%)

14:31
04/25/17
04/25
14:31
04/25/17
14:31
Options
US Steel sees a large spread trade ahead of earnings »

US Steel sees a large…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

14:25
04/25/17
04/25
14:25
04/25/17
14:25
Conference/Events
Leerink healthcare analysts hold an analyst/industry conference call »

Healthcare Analysts…

WRI

Weingarten Realty

$33.75

-0.64 (-1.86%)

14:23
04/25/17
04/25
14:23
04/25/17
14:23
Recommendations
Weingarten Realty analyst commentary  »

Weingarten Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DIS

Disney

$115.29

1.59 (1.40%)

14:19
04/25/17
04/25
14:19
04/25/17
14:19
Periodicals
Disney targets Star Wars, Frozen sequels for 2019, Deadline reports »

Disney has unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/25/17
04/25
14:17
04/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/25/17
04/25
14:16
04/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBB

Hubbell

$117.83

-3.7 (-3.04%)

14:14
04/25/17
04/25
14:14
04/25/17
14:14
Hot Stocks
Hubbell acquires connected home products maker iDevices »

iDevices announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

  • 09

    May

TWTR

Twitter

$14.80

0.085 (0.58%)

14:13
04/25/17
04/25
14:13
04/25/17
14:13
Technical Analysis
Twitter technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$74.15

0.49 (0.67%)

14:11
04/25/17
04/25
14:11
04/25/17
14:11
Options
Colgate attracts a call writer ahead of earnings »

Colgate attracts a call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

SQ

Square

$18.11

0.26 (1.46%)

14:06
04/25/17
04/25
14:06
04/25/17
14:06
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 16

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

14:05
04/25/17
04/25
14:05
04/25/17
14:05
General news
NY Fed's overnight reverse repo totaled $117.0 B, with 45 counterparties »

NY Fed's overnight…

STX

Seagate

$49.42

1.16 (2.40%)

, WDC

Western Digital

$85.77

2.66 (3.20%)

14:00
04/25/17
04/25
14:00
04/25/17
14:00
Earnings
On The Fly: What to watch in data storage earnings reports »

Companies in the data…

STX

Seagate

$49.42

1.16 (2.40%)

WDC

Western Digital

$85.77

2.66 (3.20%)

MU

Micron

$26.57

-0.75 (-2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 31

    May

  • 07

    Jun

  • 08

    Jun

14:00
04/25/17
04/25
14:00
04/25/17
14:00
General news
Stocks drifting at session highs in afternoon trading »

Stocks have been sharply…

MTBC

Medical Transcription Billing

$0.42

-0.03 (-6.67%)

13:57
04/25/17
04/25
13:57
04/25/17
13:57
Hot Stocks
Medical Transcription Billing partners with Health Compliance Network »

MTBC announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.89

0.18 (2.07%)

13:54
04/25/17
04/25
13:54
04/25/17
13:54
Hot Stocks
Sprint promotion adds free fifth line to unlimited offer »

Sprint announced that for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CMA

Comerica

$70.14

0.03 (0.04%)

13:53
04/25/17
04/25
13:53
04/25/17
13:53
Hot Stocks
Comerica raises quarterly dividend 13% to 26c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$54.57

0.92 (1.71%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Hot Stocks
Wells Fargo chairman: Stockholders sent board 'clear message of dissatisfaction' »

Commenting on the results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

D

Dominion

$77.54

-0.53 (-0.68%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Options
Downside put buyers in Dominion Resources ahead of earnings »

Downside put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 10

    May

  • 21

    May

WFC

Wells Fargo

$54.59

0.935 (1.74%)

13:50
04/25/17
04/25
13:50
04/25/17
13:50
Hot Stocks
Wells Fargo confirms all directors reelected, says votes dip as low as 53% »

Wells Fargo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PG

Procter & Gamble

$89.97

0.415 (0.46%)

13:48
04/25/17
04/25
13:48
04/25/17
13:48
Technical Analysis
Procter & Gamble technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

XLNX

Xilinx

$60.65

2.96 (5.13%)

13:46
04/25/17
04/25
13:46
04/25/17
13:46
Options
Xilinx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$20.34

1.39 (7.34%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Vivendi's UMG valued at $22B by banks seeking float, Reuters says »

Bankers aiming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHIY

Hitachi

$53.93

0.09 (0.17%)

, KKR

KKR

$17.51

0.25 (1.45%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Hitachi plans to sell chipmaking device unit to KKR, JIP, Nikkei reports »

Hitachi (HTHIY) is…

HTHIY

Hitachi

$53.93

0.09 (0.17%)

KKR

KKR

$17.51

0.25 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CLRO

ClearOne

$10.00

0.1 (1.01%)

13:43
04/25/17
04/25
13:43
04/25/17
13:43
Hot Stocks
ClearOne says awarded patent on 'beamforming' echo cancellation »

ClearOne announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.